Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Neoadjuvant Chemoradiation for Resectable Glioblastoma (NeoGlio)

NCT04209790 is registered in ClinicalTrials.gov with Geisinger Clinic as lead sponsor.

NCT NCT04209790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04209790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Neoadjuvant Chemoradiation for Resectable Glioblastoma (NeoGlio)
Lead sponsor
Geisinger Clinic
Phase
Phase 2
Overall status
Terminated
Start date
April 1, 2020
Completion date
September 14, 2022
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, high grade glioma, surgery